News & Updates
Showing Oncology articles
Showing

Daraxonrasib makes history in one of the deadliest cancers
Daraxonrasib—an oral, potent RAS(ON) multi-selective, tri-complex inhibitor—demonstrates unprecedented survival benefits in individuals with previously treated metastatic pancreatic adenocarcinoma (mPDAC) in the landmark phase III RASolute 302 study.

Cabozantinib plus nivolumab, ipilimumab improves PFS in advanced renal cell carcinoma
Adding cabozantinib to nivolumab and ipilimumab as first-line therapy, compared with placebo, results in prolonged progression-free survival (PFS) among untreated patients with advanced renal cell carcinoma (RCC), with no new safety signals seen, as shown by the results of the phase III COSMIC-313 study.

GLP-1 RAs may improve survival in cancer patients
The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes and cancer results in significantly reduced mortality and hospitalizations relative to treatment with metformin, a study has shown.





